Table 2 Clinical characteristics of candidemia episodes

Male sex

138 (52.9)

37 (49.3)

39 (54.9)

32 (54.2)

22 (66.7)

0.42

Median age (range)

65 (22–101)

67 (24–95)

63 (28–90)

68 (27–101)

61 (28–86)

0.06

Ward type

0.83

 Medical ward

110 (42.1)

30 (40.0)

35 (49.3)

23 (39.0)

14 (42.4)

 Surgical ward

51 (19.5)

16 (21.3)

10 (14.1)

14 (23.7)

7 (21.2)

 ICU

100 (38.3)

29 (38.7)

26 (36.6)

22 (37.3)

12 (36.4)

Elective admission

27 (10.3)

12 (16.0)

5 (7.0)

5 (8.5)

4 (12.1)

0.32

Malignancies

106 (40.6)

34 (45.3)

29 (40.8)

23 (39.0)

12 (36.4)

0.81

 Haematological

27 (10.3)

3 (4.0)

13 (18.3)

6 (10.2)

2 (6.1)

0.03

 Oncological

84 (32.2)

32 (42.7)

17 (23.9)

18 (30.5)

11 (33.3)

0.11

 With metastases

36 (13.8)

16 (21.3)

11 (15.5)

6 (10.2)

3 (9.1)

0.23

Diabetes

103 (39.5)

31 (41.3)

25 (35.2)

23 (39.0)

12 (36.4)

0.89

Chronic renal failure

67 (25.7)

17 (22.7)

22 (31.0)

14 (23.7)

8 (24.2)

0.67

Hepatobiliary disorders

58 (22.2)

17 (22.7)

20 (28.2)

8 (13.6)

8 (24.2)

0.25

Myocardial infarction

43 (16.5)

10 (13.3)

13 (18.3)

15 (25.4)

1 (3.0)

0.04

Cerebrovascular disease

29 (11.1)

12 (16.0)

8 (11.3)

4 (6.8)

4 (12.1)

0.44

Median (range) Charlson score

5 (0–15)

6 (0–15)

5 (0–14)

4 (0–12)

4 (0–9)

0.08

Central venous catheter

192 (73.6)

47 (62.7)

55 (77.5)

46 (78.0)

26 (78.8)

0.11

Drain

60 (23.0)

22 (29.3)

14 (19.7)

16 (27.1)

6 (18.2)

0.43

Mechanical ventilation

111 (42.5)

26 (34.7)

31 (43.7)

25 (42.4)

16 (48.5)

0.52

Total parenteral nutrition

52 (19.9)

12 (16.0)

13 (18.3)

12 (20.3)

10 (30.3)

0.37

Surgery

170 (65.1)

51 (68.0)

44 (66.0)

39 (66.1)

20 (60.6)

0.83

 Gastrointestinal surgery

41 (15.7)

18 (24.0)

5 (7.0)

9 (24.3)

5 (15.2)

0.05

Renal replacement therapy

85 (32.6)

16 (21.3)

28 (39.4)

21 (35.6)

12 (36.4)

0.10

Antimicrobial therapy

236 (90.4)

67 (89.3)

68 (95.8)

53 (89.8)

27 (81.8)

0.15

Antifungal therapy

51 (19.5)

13 (17.3)

15 (21.1)

8 (13.6)

11 (33.3)

0.13

 Azole

24 (9.2)

5 (6.7)

10 (14.1)

6 (10.2)

2 (6.1)

0.41

 Echinocandin

30 (11.5)

8 (10.7)

6 (8.5)

2 (3.4)

10 (30.3)

0.001

Immunosuppressive therapy

76 (29.1)

17 (22.7)

28 (39.4)

16 (27.1)

10 (30.3)

0.16

Neutropenia

21 (8.0)

3 (4.0)

13 (18.3)

2 (3.4)

2 (6.1)

0.004

Primary therapy

0.15

 Echinocandin

165 (73.3)

45 (76.3)

49 (81.7)

32 (60.4)

22 (71.0)

 Azole

52 (23.1)

12 (20.3)

11 (18.3)

17 (32.0)

8 (25.8)

 Others

8 (3.1)

2 (3.3)

1 (1.7)

4 (6.8)

1 (3.2)

 None

36 (13.8)

16 (21.3)

10 (14.1)

6 (10.2)

2 (6.1)

Median (range) time to primary therapy, days

1 (0–9)

2 (0–7)

1 (0–3)

2 (0–5)

1 (0–9)

0.01

Median (range) duration of therapy, days

15 (1–140)

16 (2–61)

11 (1–96)

16 (1–140)

15 (2–47)

0.01

Median (range) time to positive culture, days

12 (0–282)

11 (0–282)

14 (0–123)

14 (0–79)

37 (0–104)

0.37

Median (range) time to reporting positive culture, days

2 (0–10)

3 (0–9)

1 (0–10)

2 (1–5)

2(1–3)

<0.001

Median (range) time to species identification, days

5 (2–22)

6 (2–12)

4 (2–12)

5 (2–9)

5 (3–7)

<0.001

Median (range) SAPS II score

49 (14–103)

48 (18–95)

55 (18–93)

48 (23–103)

44 (14–72)

0.01

Median (range) Pitts' bacteraemia score

3 (0–14)

2 (0–11)

3 (0–12)

3 (0–11)

2 (0–8)

0.86

Severe sepsis at time of culture

151 (57.9)

49 (65.3)

43 (60.6)

33 (55.9)

13 (58.0)

0.08

ICU stay

131 (50.2)

36 (48.0)

35 (49.3)

30 (50.8)

16 (48.5)

0.99

Concurrent infection

127 (48.7)

33 (44.0)

36 (57.0)

30 (50.8)

16 (48.5)

0.83

Candida colonization/infection at other sites

118 (45.2)

41 (54.7)

39 (54.9)

34 (57.6)

18 (54.5)

0.99

30-day in-hospital all-cause mortality

130 (49.8)

38 (50.7)

42 (59.2)

28 (47.5)

9 (27.3)

0.03